DexCom Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon. I'm Matt Taylor, the U.S. Medical Supplies and Devices Analyst here at Jefferies, and I'm pleased to host this session with the management team from Dexcom. To my right is Jake Leach, who has been the CEO now for 11 months.
I was going to say a year. Yep. And after transitioning from COO and CTO roles. And then we also have Jereme Sylvain, the CFO, who recently was added another title, COO, as he expands his operational responsibilities. So we'll have about 25 minutes for Q&A, and I'll kick things off. Jake, I just wanted to start with a high-level question, and maybe ask you to speak for a minute about where Dexcom is on its journey to transform diabetes care, and maybe give us a brief summary and commentary about how you think the company's performing this year.
Yeah. Thanks, Matt, and thanks everyone for joining us. As we mentioned, I've been in the seat for 11 months, but long history with Dexcom. Been at Dexcom for 22 years. Started when we were a startup, basically engineering, and led a lot of our product development over the years. And when I look at the opportunity in front of us, I couldn't be more excited. If you think about just, you take a big step back and look at the number of people in the world that have diabetes, it's over 600 million and growing rapidly. You look at the number of people that have pre-diabetes on their way to diabetes, that's going to put us over 1 billion people that this technology could have a significant impact on. So, I think when we think about where we are in the trajectory, we're still very early days.
Feels like we're just getting started as we look at continued expansion with coverage. Our growth algorithm revolves around generating access for CGM insurance reimbursement around the globe, then coming to market with the right product at the right price point for the different healthcare systems. I think we've been quite effective at doing that, both in the U.S. and abroad. If you think about what we can do for an individual and help them with their understanding their behavior and how to impact their glucose levels, CGM is a very cost-effective technology. I do believe that we can reach hundreds of millions of people with this technology. Today, less than 2% of the people with diabetes are using CGM.
Just talking about an incredibly large end market, and we have a remarkably unique technology, highly differentiated, and we're going to continue to innovate on it.
I want to get to market expansion in a second, but maybe first, Jereme, since we have you here, we could talk a little bit about the numbers. You set out an LRP this past year. You're kind of well on your way there. Could you summarize the LRP and talk about how you're executing against it so far?
Yeah. Thanks, and happy to go into it and really kind of progress really top, middle, and bottom. I think it's helpful. So we had an LRP earlier this year. We went out till 2030. Really, the algorithm here is 10%+ growth per year, with gross margin expansion up into the high 60s and operating margin expansion to 29%-30% over that window. So far this year, making great progress against that. To that point, we're at the higher end of the guidance we had issued at the beginning of the year, and on track to have a record year in new patients overall. So really excited about that progress over time. Certainly that algorithm, that 10%+ algorithm, we believe is something that is going to be in effect obviously every year. Certainly some of it's contingent in the longer term based on coverage expansion.
But Jake talked about the opportunity here, and with some of the trials we've done, CONNECT being one of those trials, the opportunity for expansion of coverage is massive, and the economic benefit we can provide to society is massive. I would say we're going to progress well against that. I'm looking forward to turning the page on what I think has been an excellent year thus far. We've made great progress, even relative to 2025 on operating margin. Last year, we came in around 21%. This year, we're clocking in at 24%. So good progress there. I'd expect that progress to continue.
And we're putting all the levers in the business today, like 15-day, some of the operations work we're doing, and certainly some of the work we're doing around technology and how we deliver services efficiently, that I think are going to set us up for years to come.
Great. Maybe turning back to the near-term coverage expansion, it's been highly anticipated, kind of waiting on bated breath here. Maybe you could talk about your confidence in actually getting the coverage, what's underpinning that, and what we should think about in terms of timing.
Yeah. Very exciting time with the CONNECT data being published in the New England Journal of Medicine. And as Matt mentioned, we're awaiting CMS approval for broad type 2 coverage in the U.S. for Medicare. And really, that decision is an evidence-based decision. So they're looking at, is there enough evidence to show the benefit in the Medicare population, the Medicare beneficiaries? The CONNECT study is irrefutable, the impact that CGM had on all categories of type 2, both those using glucose-lowering medications of all types, GLP-1s, SGLT2s, even metformin, as well as those who weren't using any type of glucose-lowering medication. Significant improvements in glucose control and A1C across that whole category in just six months. And so, that data is extremely strong now that it's published in the New England Journal.
It's actually been accessed as one of the top 5% manuscripts being accessed at the New England Journal of Medicine. Very popular. We're using that to make sure we spread awareness. When it gets to CMS, we've had multiple conversations. When we submitted for this coverage in early 2025, the evidence was strong. We had a lot of real-world evidence that's continued to build. But now with CONNECT, I think it's kind of the cornerstone, the capstone on the evidence base. Now it's just a matter of time. We've been assured, we've checked in multiple levels of CMS, as well as multiple folks in Congress and the Senate. Everyone has assured us that it is progressing, and it is an evidence-based decision. We look forward to hearing back before the end of the year.
Just one other note, we do anticipate once we hear back, there's a comment period, and then there's administrative work. We're estimating if we hear back by the end of the year, we'll see that coverage really kick in in the market, for patients to experience reimbursement, middle of 2027.
Great. Maybe just remind us, how much is sort of baked into your LRP around that non-insulin type 2 coverage and growth from that segment?
Want to take that? Want me to?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
